GFAP and Wilson disease: The group from the United Kingdom (Shribmann, et al.), analyzing 40 WD patients (17 hepatic and 23 neurological) and 38 healthy subjects (HS), did not find any statistically significant difference between the groups (WD = 84 ng/mL; HS = 84 ng/L); also, the WD phenotype has no impact on GFAP level (neurological = 84 ng/L; hepatic = 80 ng/L) [166].